Major Depressive Disorder Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics

DelveInsight's "Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Major Depressive Disorder, historical and forecasted epidemiology as well as the Major Depressive Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Major Depressive Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Major Depressive Disorder Market Forecast
https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Key Highlights from Major Depressive Disorder market Report:
• The Major Depressive Disorder market size was valued approximately ~USD 7,165 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In April 2025, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on developing innovative treatments for brain health disorders, has announced that the first patient has been dosed in its Phase 3 Emerge study. The study is evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD, for the treatment of major depressive disorder (MDD). The Emerge trial will assess the efficacy and safety of MM120 ODT 100 μg compared to a placebo and is expected to enroll approximately 140 participants in the United States. This marks the third Phase 3 study for MM120 ODT, following the ongoing Voyage and Panorama studies in generalized anxiety disorder (GAD).
• In March 2025, Johnson & Johnson (J&J) has decided to discontinue its Phase III major depressive disorder (MDD) program for aticaprant, citing "insufficient efficacy in the target population." The VENTURA program, which tested the experimental drug as an adjunctive treatment for MDD, consisted of five Phase III trials. Despite the lack of efficacy, the company stated that aticaprant was found to be safe and well-tolerated throughout the program. Complete data from the VENTURA trials will be shared at an upcoming medical meeting.
• In January 2025, HMNC Brain Health (HMNC) has completed the randomization process in its placebo-controlled Phase IIb OLIVE trial for BH-200, a vasopressin V1b receptor antagonist, aimed at treating major depressive disorder (MDD). The trial, designed to evaluate the safety and efficacy of the therapy alongside a predictive companion diagnostic, involves 338 outpatients. It is part of the company's Nelivabon program, which targets MDD in patients with HPA-axis dysfunction, a condition that affects about 30% of all MDD cases.
• In 2023, the United States held the largest share of the Major Depressive Disorder Treatment Market, representing about 78% of the total market size across the 7MM. This was significantly higher than the market sizes in other key regions, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2023, Germany held the largest Major Depressive Disorder market size among European countries, reaching approximately USD 531 million, whereas Italy had the smallest market size for Major Depressive Disorder at around USD 129 million.
• Japan's Major Depressive Disorder market size was estimated at approximately USD 142 million in 2023, representing 2% of the total market across the 7MM.
• DelveInsight's estimates indicate that the total diagnosed prevalent cases of Major Depressive Disorder in the 7MM were approximately 44 million in 2023.
• In 2023, the United States had the highest number of diagnosed prevalent cases of Major Depressive Disorder, totaling around 22 million, with numbers anticipated to increase in the future.
• In 2023, Germany had the highest number of diagnosed prevalent cases of Major Depressive Disorder among European countries, with approximately 6.8 million cases, followed by the UK with around 4 million cases. Conversely, Spain had the lowest diagnosed prevalence, with about 1.9 million cases.
• In 2023, Japan had an estimated 3 million diagnosed prevalent cases of Major Depressive Disorder, representing about 7% of the total in the 7MM.
• Key Major Depressive Disorder Companies: Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Minerva Neurosciences, Luye Pharma, Relmada Therapeutics, BioLite Inc., VistaGen Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, and others
• Key Major Depressive Disorder Therapies: VRAYLAR (Cariprazine), Zuranolone (SAGE-217/BIIB125), Seltorexant (JNJ42847922), SAGE-217, REL-1017, SP-624, SPL026, PDC-1421, and others
• The Major Depressive Disorder epidemiology based on gender analyzed that females were more affected as compared to males in the United States
• The Major Depressive Disorder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Major Depressive Disorder pipeline products will significantly revolutionize the Major Depressive Disorder market dynamics.

Major Depressive Disorder Overview:
Major Depressive Disorder (MDD), also known as clinical depression, is a common and serious mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in most activities. It affects how a person thinks, feels, and behaves, often leading to emotional and physical problems. Symptoms include fatigue, changes in appetite or sleep, difficulty concentrating, and thoughts of death or suicide. To be diagnosed with MDD, these symptoms must last for at least two weeks and interfere with daily functioning. Treatment typically involves a combination of psychotherapy, medication, and lifestyle changes.

Get a Free sample for the Major Depressive Disorder Market Report:
https://www.delveinsight.com/report-store/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Major Depressive Disorder Epidemiology Insights:
The epidemiology section dedicated to major depressive disorder offers insights into the historical and present patient populations for this condition, along with projected trends across seven major countries. This section aids in understanding the reasons behind current and predicted trends by examining multiple studies and insights from key opinion leaders.

Major Depressive Disorder Epidemiology Segmentation:
The Major Depressive Disorder market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Major Depressive Disorder
• Prevalent Cases of Major Depressive Disorder by severity
• Gender-specific Prevalence of Major Depressive Disorder
• Diagnosed Cases of Episodic and Chronic Major Depressive Disorder

Download the report to understand which factors are driving Major Depressive Disorder epidemiology trends @ Major Depressive Disorder Epidemiology Forecast
https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Major Depressive Disorder Therapies and Key Companies
• VRAYLAR (Cariprazine): AbbVie and Gedeon Richter Plc.
• Zuranolone (SAGE-217/BIIB125): Sage Therapeutics/Biogen Inc., /Shionogi
• Seltorexant (JNJ42847922): Janssen Pharmaceuticals/Minerva Neuroscience
• SAGE-217: Sage Therapeutics
• REL-1017: Relmada Therapeutics, Inc
• SP-624: Sirtsei Pharmaceuticals, Inc.
• SPL026: Small Pharma
• PDC-1421: BioLite Inc

Emerging Major Depressive Disorder drugs Uptake:
The pharmaceutical section within the major depressive disorder report comprises an in-depth analysis of marketed drugs for this condition as well as drugs in advanced stages (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) within the major depressive disorder pipeline.
"The Phase II trial demonstrated a positive safety profile, good tolerability, and promising pharmacokinetics of REL-1017. Currently, it is undergoing advanced-stage development in Phase III trials for treating Major Depressive Disorder, both as an adjunctive therapy and as a standalone treatment."

Discover more about therapies set to grab major Major Depressive Disorder market share @ Major Depressive Disorder Treatment Landscape
https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Major Depressive Disorder Market Forecast:
• The market perspective presented in the report on major depressive disorder develops a comprehensive understanding of historical, present, and projected trends in the major depressive disorder market. It achieves this by assessing the influence of existing therapies, identifying unmet needs within Major Depressive Disorder, and evaluating the demand for advanced technology.
• The Major Depressive Disorder market drivers include - there is an increasing awareness that Major Depressive Disorder can be reliably diagnosed and treated in primary care settings using antidepressant medications and/or brief structured psychological therapies.

Scope of the Major Depressive Disorder Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Major Depressive Disorder Companies: Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Luye Pharma, Relmada Therapeutics, BioLite Inc., VistaGen Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, and others
• Key Major Depressive Disorder Therapies: VRAYLAR (Cariprazine), Zuranolone (SAGE-217/BIIB125), Seltorexant (JNJ42847922), SAGE-217, REL-1017, SP-624, SPL026, PDC-1421, and others
• Major Depressive Disorder Therapeutic Assessment: Major Depressive Disorder current marketed and Major Depressive Disorder emerging therapies
• Major Depressive Disorder Market Dynamics: Major Depressive Disorder market drivers and Major Depressive Disorder market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Major Depressive Disorder Unmet Needs, KOL's views, Analyst's views, Major Depressive Disorder Market Access and Reimbursement


To know more about Major Depressive Disorder companies working in the treatment market, visit @ Major Depressive Disorder Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Major Depressive Disorder Market Report Introduction
2. Executive Summary for Major Depressive Disorder
3. SWOT analysis of Major Depressive Disorder
4. Major Depressive Disorder Patient Share (%) Overview at a Glance
5. Major Depressive Disorder Market Overview at a Glance
6. Major Depressive Disorder Disease Background and Overview
7. Major Depressive Disorder Epidemiology and Patient Population
8. Country-Specific Patient Population of Major Depressive Disorder
9. Major Depressive Disorder Current Treatment and Medical Practices
10. Major Depressive Disorder Unmet Needs
11. Major Depressive Disorder Emerging Therapies
12. Major Depressive Disorder Market Outlook
13. Country-Wise Major Depressive Disorder Market Analysis (2019-2032)
14. Major Depressive Disorder Market Access and Reimbursement of Therapies
15. Major Depressive Disorder Market Drivers
16. Major Depressive Disorder Market Barriers
17. Major Depressive Disorder Appendix
18. Major Depressive Disorder Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Major Depressive Disorder Pipeline https://www.delveinsight.com/report-store/major-depressive-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Major Depressive Disorder Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Major Depressive Disorder market. A detailed picture of the Major Depressive Disorder pipeline landscape is provided, which includes the disease overview and Major Depressive Disorder treatment guidelines.

Major Depressive Disorder Epidemiology https://www.delveinsight.com/report-store/major-depressive-disorder-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Major Depressive Disorder Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Major Depressive Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
• Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
• Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market
• Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market
• Drug-eluting Stents Market Market: https://www.delveinsight.com/report-store/drug-eluting-stents-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.